NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

ABCL | NASDAQ

$13.91 -$0.68 | -4.66%
SIGNAL:Signal available — unlock to view |2026-09-25 |F&G 84 |RSI 68.9

Company Overview:

Market Cap: $4.51B
Trailing PE: N/A
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $2.75 - $15.02

5.8 Year ABCL Performance Metrics:

Total Return (with DRIP): -76.4% (-22.03% CAGR)
Total Return (no DRIP): -76.4% (-22.03% CAGR)
Share Price: -76.4% (-22.03% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $2,362
Total Return $ (with DRIP): -$7,638
ABCL Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
ABCL Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

ABCL Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

ABCL - Revenue
ABCL Revenue CAGR:1Y: -76.29%2Y: -25.63%5Y: -31.90%10Y: 0.00%
ABCL - Earnings Per Share (EPS)
ABCL EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Net Income
🔓 See the full chart40% off right now · 7-day free trial
ABCL Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - EBITDA
🔓 See the full chart40% off right now · 7-day free trial
ABCL EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Free Cash Flow
🔓 See the full chart40% off right now · 7-day free trial
ABCL Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: -28.17%10Y: 0.00%
ABCL - Free Cash Flow / Share
🔓 See the full chart40% off right now · 7-day free trial
ABCL Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Operating Income
🔓 See the full chart40% off right now · 7-day free trial
ABCL Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Gross Profit
🔓 See the full chart40% off right now · 7-day free trial
ABCL Gross Profit CAGR:1Y: -76.29%2Y: -25.63%5Y: -29.96%10Y: 0.00%
ABCL - Shares Outstanding
🔓 See the full chart40% off right now · 7-day free trial
ABCL Shares Outstanding CAGR:1Y: 2.36%2Y: 1.91%5Y: 2.34%10Y: 0.00%
ABCL - Share Buybacks
🔓 See the full chart40% off right now · 7-day free trial
ABCL Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Stock-Based Comp
🔓 See the full chart40% off right now · 7-day free trial
ABCL Stock-Based Comp CAGR:1Y: -13.52%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Expenses
🔓 See the full chart40% off right now · 7-day free trial
ABCL Expenses CAGR:1Y: -84.05%2Y: -67.18%5Y: -43.62%10Y: 0.00%
ABCL - Revenue vs Net Income
🔓 See the full chart40% off right now · 7-day free trial
ABCL - EPS vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
ABCL - EPS vs PE Ratio
🔓 See the full chart40% off right now · 7-day free trial
ABCL - FCF vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
ABCL - FCF vs Stock Based Comp
🔓 See the full chart40% off right now · 7-day free trial
ABCL - Cash & Debt
🔓 See the full chart40% off right now · 7-day free trial
ABCL - Revenue by Segment
🔓 See the full chart40% off right now · 7-day free trial
ABCL Revenue CAGR:1Y: -76.29%2Y: -25.63%5Y: -31.90%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ABCL - REVENUE: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
ABCL Actual Revenue CAGR:1Y: -76.29%2Y: -25.63%5Y: -31.90%10Y: 0.00%
ABCL - EPS: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
ABCL Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - NET INCOME: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
ABCL Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - EBITDA: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
ABCL Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

ABCL - Net Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
ABCL Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Gross Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
ABCL Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 2.84%10Y: 0.00%
ABCL - Price to Earnings
🔓 See the full chart40% off right now · 7-day free trial
ABCL Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Price To Sales Ratio
🔓 See the full chart40% off right now · 7-day free trial
ABCL Price To Sales Ratio CAGR:1Y: 888.20%2Y: 130.27%5Y: 22.28%10Y: 0.00%
ABCL - Return on Capital Employed
🔓 See the full chart40% off right now · 7-day free trial
ABCL Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
ABCL - Return on Invested Capital
🔓 See the full chart40% off right now · 7-day free trial
ABCL Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for ABCL

Based on past 5.8-year performance, here are ABCL growth metrics:

Share price CAGR of -22.03%
Dividend CAGR of +0%

Using ABCL CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

ABCL (DRIP)ABCL - No DRIP
Current Price$13.91$13.91
Start Shares718.91718.91
Start Value$10,000$10,000
  
After 10 years:
Final Share Count718.91718.91
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$1.16$13.91
Total Dividends$0$0
Final Value$830$10,000

Estimated Future Value + Dividends - ABCL

NOTE: Above numbers are our estimate based on ABCL's Dividend and Price CAGR over past 5.8 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

AbCellera Biologics Inc. (ABCL) had its IPO on 2020-12-11, and is traded on NASDAQ stock exchange.

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

ABCL website: https://www.abcellera.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — ABCL

Value from:
Pay up to today
—
vs current price $13.91
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →